Astragalin: A Bioactive Phytochemical with Potential Therapeutic Activities

Table 5

Anticancer activities of astragalin in vitro and in vivo.

Type of cancer	Cell line	Dose/concentration	Molecular targets	References
Leukemia	HL-60	6 ± 1 µM	Bax^↑, Bcl-2^↓, caspase-3/-7^Act, JNK/SAPK^┴, and ERK 1/2^┴	[15]
Hepatocellular	HepG2, Huh-7, and H22	—	HK2^┴ and miR-125b^↑	[150]
Skin	HaCaT, A375P, and SK-MEL-2	50 and 100 M/mL	p38 MAPK^↓, phospho-MSK1^↓, γ-H2AX^↓, caspase-9/-3^Act, Bax^Act, PARP cleavage, cyclin D1^↓, Mcl-1^↓, and SOX10^┴	[151, 152]
Lung	A549, H1299, H226, H838, H23, H1437, H125, H2009, and H2087	5, 40 µg/mL (A549) and 20 µg/mL (H1299)	Bax:Bcl-2^↑, caspase-9/-3^↑, p-IKK-β^↓, NF-κB p65^┴, TNF-α^┴, ERK-1/2^┴, JNK^↑, PI3K/Akt^┴, DDH^┴, DRP-1^↓, pro-caspase-3/-8^↑, and Bax^↑	[145, 153]
Breast	ZR-75-1, T47D, BT20, MCF-1, and MCF-7	—	DDH^┴, DRP-1^↓, pro-caspase-3/-8^↑, and Bax^↑	[153]
Gastric	AGS, SC-M1, NUGC-1, NUGC-3, and KOTA-III	—	DDH^┴, DRP-1^↓ pro-caspase-3/-8^↑, and Bax^↑	[153]

^↑Upregulation; ^↓downregulation; ^┴inhibition.